Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05295979
PHASE2

Chinese Medicine for Patients With Psoriasis

Sponsor: Chinese University of Hong Kong

View on ClinicalTrials.gov

Summary

Psoriasis is an inflammatory skin disease with huge negative impact on the quality of life of the patients, and has an overall prevalence of 2% to 3% in the general population. Plaques psoriasis is the most common type of the disease and presents red, well demarcated, and silvery plaques mainly localized in the umbilical and lumbosacral area as well as in the elbows, knees, and scalp. Currently, pharmacological treatments such as retinoids, corticosteroids, vitamin D analogs and biologics remain the main options for most psoriasis patients. However, side effect and high cost barred many ordinary psoriasis patients. A Chinese medicine formula "Inflammatory skin disease formula (ISDF)" was prescribed by Prof. Lin for many years and observed to be effective in relieving atopic dermatitis and psoriasis patients' clinical manifestations. In this study, subjects with psoriasis will be randomized into treatment group of "ISDF" or placebo group for 12 weeks.

Official title: Development of a Novel Chinese Medicine Formula for the Treatment of Psoriasis: A Randomized, Double-blinded, Placebo-controlled Trial

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2023-03-20

Completion Date

2026-03-27

Last Updated

2026-07-27

Healthy Volunteers

No

Conditions

Interventions

DRUG

Inflammatory skin disease formula

ISDF granules (10.85g twice daily) for 12 weeks

DRUG

Placebo

Placebo granules (10.85g twice daily) for 12 weeks

Locations (1)

Hong Kong Institute of Integrative Medicine

Hong Kong, Hong Kong